Latest

Learn how lung cancer MRD ctDNA testing detects molecular residual disease, what positive and negative results mean, how it can precede recurrence on scans, and why treatment decisions still require clinical context.

Minimal Residual Disease ctDNA Test for Lung Cancer: Recurrence Monitoring, MRD, and Tumor DNA

Learn what MSI testing means in lung cancer, how MSI-H, MSS, dMMR, and pMMR results differ, how NGS, PCR, and IHC are used, and why this rare biomarker can matter for immunotherapy and hereditary evaluation.

MSI Test for Lung Cancer: Microsatellite Instability, Mismatch Repair, and Result Meaning

Learn how Napsin A IHC supports lung adenocarcinoma diagnosis, what positive granular cytoplasmic staining means, why negative results do not exclude lung cancer, and when other tumor origins must be considered.

Napsin A IHC Test for Lung Cancer: Adenocarcinoma Marker, Tumor Origin, and Positive...

Non-Small Cell Lung Cancer Biomarker Test: Driver Mutations, PD-L1, and Molecular Profile

Learn what an NSE blood test means in small cell lung cancer, why levels can be high, how hemolysis causes false elevations, and how serial NSE trends may support treatment and recurrence monitoring.

NSE Test for Lung Cancer: Small Cell Lung Cancer Marker, High Levels, and...

Understand NTRK fusion testing in lung cancer, including tumor-agnostic meaning, RNA NGS, pan-TRK IHC, positive results, negative-result limits, and next steps.

NTRK Fusion Test for Lung Cancer: Gene Fusion, Tumor-Agnostic Marker, and Molecular Meaning

Diagnostics

Home Diagnostics Page 9

Understand MSH6 mutation testing for Lynch syndrome, including isolated MSH6 loss, MSI findings, germline variants, colorectal and endometrial cancer risk, surveillance, and next steps.

MSH6 Mutation Test: Lynch Syndrome, Colon Cancer, Mismatch Repair, and Variant...

Understand MUTYH mutation testing, including biallelic versus monoallelic results, polyposis and colon cancer risk, variant meaning, surveillance, and family testing.

MUTYH Mutation Test: Colon Cancer, Polyposis, Variant Meaning, and Hereditary Risk

Learn what a MYC rearrangement FISH test detects, how positive and negative results are interpreted, and what MYC means in Burkitt, high-grade B-cell lymphoma, and leukemia.

MYC Rearrangement Test: Lymphoma, Leukemia, High-Grade Disease, and FISH Result

Understand MYD88 L265P testing in Waldenström macroglobulinemia and lymphoma, including positive and negative results, test methods, CXCR4 context, and treatment meaning.

MYD88 Mutation Test: Waldenstrom Macroglobulinemia, Lymphoma, L265P Variant, and Meaning

Understand NPM1 mutation testing in AML, including prognosis, FLT3 risk groups, molecular MRD monitoring, positive and negative results, and what changing NPM1 levels mean.

NPM1 Mutation Test: AML Prognosis, MRD Monitoring, Mutation Status, and Meaning

Understand NRAS mutation testing in melanoma and colorectal cancer, including positive and negative results, RAS treatment implications, methods, and follow-up.

NRAS Mutation Test: Melanoma, Colon Cancer, Mutation Status, and Result Meaning

Learn what an NTRK fusion test means, how NTRK1/2/3 fusions are detected, why they are tumor-agnostic markers, and how positive results guide TRK therapy.

NTRK Fusion Test: Gene Fusion, Tumor-Agnostic Marker, Positive Result, and Meaning

Understand PALB2 mutation testing, hereditary breast, pancreatic, and ovarian cancer risks, DNA-repair biology, variant meaning, screening, and family testing.

PALB2 Mutation Test: Breast, Pancreatic, Ovarian Cancer Risk, DNA Repair, and...

Understand PDGFRA mutation testing in GIST, including exon 12, 14, and 18 variants, D842V meaning, imatinib resistance, avapritinib, and result interpretation.

PDGFRA Mutation Test: GIST, Mutation Status, Exon Variants, and Result Meaning

Understand PIK3CA mutation testing in breast cancer and solid tumors, including PI3K pathway biology, hotspot variants, liquid biopsy, and targeted treatment meaning.

PIK3CA Mutation Test: Breast Cancer, Solid Tumors, PI3K Pathway, and Mutation...

Understand PML-RARA fusion testing in acute promyelocytic leukemia, including urgent diagnosis, ATRA/ATO treatment, RT-PCR methods, molecular remission, and MRD monitoring.

PML-RARA Fusion Test: Acute Promyelocytic Leukemia, Gene Fusion, Diagnosis, and Monitoring

Understand what a PMS2 mutation test means, how it relates to Lynch syndrome and mismatch repair, why pseudogene interference matters, and what positive, VUS, or negative results may mean for cancer risk and follow-up.

PMS2 Mutation Test: Lynch Syndrome, Colon Cancer, Mismatch Repair, and Variant...

Learn how to interpret PTEN mutation testing, including germline PHTS results, tumor-only PTEN loss, PI3K-AKT-mTOR pathway effects, cancer risk, VUS findings, assay limits, and follow-up.

PTEN Mutation Test: Tumor Suppressor Gene, Cancer Risk, Pathway Alteration, and...

Learn what a RET fusion test detects in lung and thyroid cancer, how RNA and DNA testing differ, what positive or negative results mean, and how RET fusions can guide targeted therapy and resistance testing.

RET Fusion Test: Lung Cancer, Thyroid Cancer, Gene Fusion, and Result...

Understand RUNX1 mutation testing in AML and MDS, including modern WHO/ICC classification, ELN risk, prognosis, somatic versus germline findings, VAF limits, MRD context, and follow-up.

RUNX1 Mutation Test: AML, Myelodysplastic Syndrome, Mutation Status, and Prognosis

Learn how SMARCB1/INI1 loss testing is interpreted in rhabdoid tumors and sarcomas, what complete nuclear loss means, which tumors can share the pattern, when molecular or germline testing is needed, and how results may affect treatment.

SMARCB1/INI1 Loss Test: Rhabdoid Tumor, Sarcoma, IHC Loss, and Interpretation

Solid Tumor NGS Panel Test: Tumor Mutations, Gene Fusions, Copy Number...

Learn how SS18-SSX fusion testing confirms synovial sarcoma, how RNA NGS, FISH, RT-PCR, and fusion-specific IHC differ, what positive or negative results mean, and how the diagnosis affects modern treatment.

SS18-SSX Fusion Test: Synovial Sarcoma, Gene Fusion, and Molecular Diagnosis

Learn how TFE3 fusion testing classifies kidney and soft-tissue tumors, how IHC, FISH, and RNA NGS differ, what positive or negative results mean, and why the fusion partner and tumor context matter.

TFE3 Fusion Test: Kidney Cancer, Soft Tissue Tumor, Translocation Marker, and...

Understand what a TP53 mutation test means in AML and MDS, including multi-hit status, prognosis, treatment implications, transplant planning, and germline versus somatic findings.

TP53 Mutation Test in Leukemia High-Risk Blood Cancer, Mutation Status, and...

1...8910...92 Page 9 of 92